WTO inks vaccines patent waiver deal after lengthy session

17 June 2022
wto_ip_trade_big

World Trade Organization (WTO) members unveiled a new package of trade accords late Thursday following a marathon negotiating session in Geneva, Switzerland, headlined by deals to create flexible intellectual property rules covering COVID-19 vaccines, as well as other trade issues such as global fishing subsidies.

Under an arrangement known as compulsory licensing, member countries agreed to a vaccine patent waiver as a way to boost supplies of COVID-19 shots to lower income countries.

The debate overcame a protracted fight between the USA and China over the Biden administration’s demand that China be clearly excluded from the deal – for fear that it would enable China to steal US technologies.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Today's issue

Company Spotlight





More Features in Pharmaceutical